TESLAC
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESLAC is an injectable small-molecule NDA approved in 1969 by Bristol Myers Squibb. The specific indication and mechanism of action are not currently documented in available data. This is a legacy product approaching loss of exclusivity.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting team and focus on legacy management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TESLAC offers limited career growth opportunity given the zero linked job openings and approaching LOE status. This role is best suited for professionals seeking legacy product management or transition planning experience rather than expansive career trajectory.
Brand ManagerField Sales
Worked on TESLAC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.